Novavax begins COVID-19, flu combination vaccine trial
Novavax has launched a Phase I/II study evaluating a combination vaccine for the prevention of both COVID-19 and seasonal influenza, the US biotech company announced today.
The study will evaluate the safety and immunogenicity of a combination vaccine, using Novavax’s flu and COVID-19 vaccines.
The trial combines the company’s recombinant protein-based COVID-19 jab NVX-CoV2372 and NanoFlu vaccine candidates with Novavax’s Matrix-M adjuvant into a single formulation.
The trial will aim to enrol 640 healthy adults, aged 50- to 70-years-old, who will have been either previously infected with the SARS-CoV-2 virus or vaccinated with an authorised vaccine at least eight weeks prior to enrolment.
"This study is the first-of-its-kind to evaluate the vaccine's potential to induce a robust immune response, augmented by our Matrix-M adjuvant, against two life-threatening diseases simultaneously," said Gregory M. Glenn, president of research and development, Novavax.
Read more: https://www.pharmatimes.com/news/novavax_begins_covid-19,_flu_combination_vaccine_trial_1376450
The study will evaluate the safety and immunogenicity of a combination vaccine, using Novavax’s flu and COVID-19 vaccines.
The trial combines the company’s recombinant protein-based COVID-19 jab NVX-CoV2372 and NanoFlu vaccine candidates with Novavax’s Matrix-M adjuvant into a single formulation.
The trial will aim to enrol 640 healthy adults, aged 50- to 70-years-old, who will have been either previously infected with the SARS-CoV-2 virus or vaccinated with an authorised vaccine at least eight weeks prior to enrolment.
"This study is the first-of-its-kind to evaluate the vaccine's potential to induce a robust immune response, augmented by our Matrix-M adjuvant, against two life-threatening diseases simultaneously," said Gregory M. Glenn, president of research and development, Novavax.
Read more: https://www.pharmatimes.com/news/novavax_begins_covid-19,_flu_combination_vaccine_trial_1376450
